Form 4: RELMADA Therapeutics CFO Granted 600,000 Stock Options

RELMADA Therapeutics' Chief Financial Officer, Maged Shenouda, was granted 600,000 stock options with an exercise price of $0.67, vesting quarterly starting September 26, 2025.

Summary

• Maged Shenouda, Chief Financial Officer of RELMADA Therapeutics, Inc. (RLMD), was granted 600,000 stock options.
• The stock options have an exercise price of $0.67 per share.
• The options were granted on June 26, 2025, and will begin vesting on September 26, 2025.
• Vesting will occur in 16 equal quarterly installments.
• The expiration date for these stock options is June 26, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management retention and alignment with shareholder interests, though it does not directly reflect operational or financial performance.

Positives

• The grant of 600,000 stock options to the Chief Financial Officer aligns management incentives with long-term shareholder value creation.
• The long expiration date of June 26, 2035, provides a significant window for the options to potentially become in-the-money, incentivizing sustained performance.

Negatives

• No explicit negative financial or operational information is disclosed in this Form 4 filing.

Risks

• The value of the stock options is contingent on the future performance of RELMADA Therapeutics' common stock exceeding the exercise price of $0.67.
• If the company's stock price does not appreciate above the exercise price, the options may expire worthless, providing no financial benefit to the holder.

Future Outlook

The stock options are structured to vest over a period of four years (16 quarterly installments), indicating a long-term incentive for the Chief Financial Officer and aligning their interests with the company's sustained performance.

Management Comments

• No specific management comments or statements are included in this Form 4 filing, as it is a standard disclosure document for insider transactions.

Industry Context

This Form 4 filing reflects a standard practice of providing equity-based compensation to key executives in the biotechnology and pharmaceutical industries to align their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of 600,000 stock options to a Chief Financial Officer is a common form of executive compensation in the biotech sector, typically used to incentivize long-term performance and retention.
• To fully assess the competitiveness and alignment with industry benchmarks, the specific size of the grant and exercise price would need to be compared against peer companies of similar market capitalization and stage of development, such as those in the emerging biopharmaceutical space.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are disclosed in this Form 4 filing.

Related Party Transactions

• The grant of stock options to the Chief Financial Officer is a direct transaction between the company and an executive, which is a common form of compensation and aligns management incentives with company performance.

Stakeholder Impact

• Shareholders: Potential for increased alignment of management's interests with shareholder value creation, but also potential for future dilution if options are exercised.
• Management: The Chief Financial Officer receives a significant equity stake, providing a strong long-term incentive for performance and retention.

Next Steps

• The granted stock options will begin vesting in 16 equal quarterly installments commencing on September 26, 2025.

Key Dates

Keywords

RELMADA Therapeutics, RLMD, stock options, insider transaction, Form 4, Maged Shenouda, Chief Financial Officer, equity compensation, beneficial ownership